Generic Semaglutide Coming to Market
Online pharmacy PharmaGiant.com announced it will soon offer generic semaglutide, the active ingredient in popular diabetes and weight-loss drugs. The move is aimed at increasing affordable access to the medication for U.S. patients facing high prescription costs. This could provide significant relief for those paying out-of-pocket for brand-name versions.
Danish pharmaceutical company Novo Nordisk is the sole manufacturer of three FDA-approved drugs containing semaglutide: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management. There are currently no FDA-approved generic versions of semaglutide. The primary U.S. patents for semaglutide are not expected to expire until around 2031 or 2032. This long patent life allows the manufacturer to maintain market exclusivity. In other countries, such as India and Brazil, key patents are expiring as early as March 2026, paving the way for generic competition sooner. The list price for brand-name semaglutide drugs in the U.S. has been a significant barrier to access, with costs for Ozempic and Wegovy exceeding $1,000 and $1,349 per month, respectively. In response to public and political pressure, Novo Nordisk has announced it will cut the U.S. list prices for Wegovy, Ozempic, and Rybelsus to $675 per month, effective January 1, 2027. Due to high demand and previous drug shortages, some patients have turned to compounding pharmacies for access to semaglutide. These pharmacies create customized medications and are regulated by state pharmacy boards, but their products are not FDA-approved and do not undergo the same safety and efficacy testing as commercially produced drugs. The FDA has issued multiple warnings regarding compounded semaglutide. The agency has received hundreds of reports of adverse events, including some requiring hospitalization, which may be linked to dosing errors from these compounded versions. A key concern raised by the FDA is that some compounding pharmacies may be using salt forms of the active ingredient, such as semaglutide sodium and semaglutide acetate. These are different from the base ingredient in the approved drugs and have not been proven to be safe or effective. With semaglutide officially removed from the FDA's drug shortage list in February 2025, the legal allowance for pharmacies to compound "essentially a copy" of the commercial drugs has become much stricter. Both Novo Nordisk and Eli Lilly, maker of a similar drug, have sent cease-and-desist letters to entities selling compounded versions.
